{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:14:32Z","timestamp":1789229672677,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00045","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:40:36Z","timestamp":1551159636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Robert Frank","family":"Cornell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelton","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houston","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"New Eng J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin Lymph Myeloma Leukemia."},{"key":"B3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular complications of novel multiple myeloma treatments","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1161\/CIRCULATIONAHA.113.002702","article-title":"Venous thromboembolism and cancer","volume":"128","author":"Piazza","year":"2013","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1177\/1076029613481844","article-title":"Venous thromboembolism in hospitalized patients with active cancer","volume":"19","author":"Piazza","year":"2013","journal-title":"Clin Appl Thromb Hemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bjh.14970","article-title":"Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma","volume":"180","author":"Fradley","year":"2018","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ctrv.2008.02.003","article-title":"A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma","volume":"34","author":"Hicks","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8067","DOI":"10.1200\/jco.2011.29.15_suppl.8067","article-title":"Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide","volume":"29","author":"Mikhael","year":"2011","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.amjmed.2009.11.017","article-title":"Adherence to pharmacological thromboprophylaxis orders in hospitalized patients","volume":"123","author":"Fanikos","year":"2010","journal-title":"Am J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens","author":"Storrar","year":"2018","journal-title":"Br J Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2174\/138945012800564059","article-title":"Apixaban: a new player in the anticoagulant class","volume":"13","author":"Agrawal","year":"2012","journal-title":"Curr Drug Targets"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2165\/11635730-000000000-00000","article-title":"New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function","volume":"72","author":"Poulsen","year":"2012","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1302\/0301-620X.94B2.27850","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials","volume":"94","author":"Raskob","year":"2012","journal-title":"J Bone Joint Surg Br."},{"key":"B25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e18559","DOI":"10.1200\/jco.2012.30.15_suppl.e18559","article-title":"Incidence of venous thromboembolic events (VTE) in multiple myeloma patients receiving lenalidomide (LEN) with and without dexamethasone (DEX)","volume":"30","author":"Brandenburg","year":"2012","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(12)70024-5","article-title":"Risk and management of thrombosis in multiple myeloma","author":"Leebeek","year":"2012","journal-title":"Thromb Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/nrcardio.2012.122","article-title":"Third universal definition of myocardial infarction","volume":"9","author":"Thygesen","year":"2012","journal-title":"Nat Rev Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","article-title":"An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Sacco","year":"2013","journal-title":"Stroke"},{"key":"B36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1200\/JCO.2017.35.15_suppl.509","article-title":"Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: a pilot study (MYELAXAT)","volume":"35","author":"Pegourie","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:40:38Z","timestamp":1551159638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":37,"alternative-id":["10.3389\/fonc.2019.00045"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00045","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"article-number":"45"}}